Literature DB >> 26945563

Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: Association with extent of skin sclerosis.

Koichi Yanaba1, Mitsuha Hayashi1, Yuki Yoshihara1, Hidemi Nakagawa1.   

Abstract

The interaction of programmed death-1 (PD-1) with its ligand, programmed death ligand-1 (PD-L1), has been considered to play a key role in the negative regulation of immune responses. Patients with diffuse cutaneous systemic sclerosis (SSc) had higher levels of soluble PD-1 (sPD-1) than those with limited cutaneous SSc and healthy individuals. Serum sPD-1 levels positively correlated with the severity of skin sclerosis. In contrast, serum sPD-L1 levels were significantly increased in patients with SSc compared with healthy individuals. Moreover, serum sPD-L1 levels were not associated with the extent of skin sclerosis and were elevated not only in patients with diffuse cutaneous SSc, but also in those with limited cutaneous SSc. These results suggested that serum sPD-1 levels may increase in patients with SSc and correlate with the severity of skin sclerosis. PD-1/PD-L1 interaction may contribute to the development of skin sclerosis in SSc.
© 2016 Japanese Dermatological Association.

Entities:  

Keywords:  enzyme-linked immunoassay; programmed death ligand-1; programmed death-1; skin sclerosis; systemic sclerosis

Mesh:

Substances:

Year:  2016        PMID: 26945563     DOI: 10.1111/1346-8138.13339

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  8 in total

Review 1.  Pathogenesis of systemic sclerosis-current concept and emerging treatments.

Authors:  Masutaka Furue; Chikage Mitoma; Hiroki Mitoma; Gaku Tsuji; Takahito Chiba; Takeshi Nakahara; Hiroshi Uchi; Takafumi Kadono
Journal:  Immunol Res       Date:  2017-08       Impact factor: 2.829

2.  6-Sulfo LacNAc monocytes are quantitatively and functionally disturbed in systemic sclerosis patients.

Authors:  Laure Ricard; Déborah Eshagh; Lama Siblany; Frédéric de Vassoigne; Florent Malard; Charlotte Laurent; Pauline Beurier; Vincent Jachiet; Sébastien Rivière; Olivier Fain; Mohamad Mohty; Béatrice Gaugler; Arsène Mekinian
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

3.  Percentages of PD-1+CD4+T cells and PD-L1+DCs are increased and sPD-1 level is elevated in patients with immune thrombocytopenia.

Authors:  Yingying Wang; Nannan Pang; Xinyou Wang; Ying Liu; Xiujuan Wang; Lei Wang; Mingling Sun; Halida Yasen; Fang Zhao; Wenxia Fan; Xinhong Guo; Jianbing Ding
Journal:  Hum Vaccin Immunother       Date:  2018-01-18       Impact factor: 3.452

4.  Soluble B and T Lymphocyte Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an Increased Risk of Mortality.

Authors:  Anna Lange; Jonas Sundén-Cullberg; Anders Magnuson; Olof Hultgren
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

5.  Increase of Soluble Programmed Cell Death Ligand 1 in Patients with Chronic Hepatitis C.

Authors:  Satoshi Yamagiwa; Toru Ishikawa; Nobuo Waguri; Soichi Sugitani; Kenya Kamimura; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Shuji Terai
Journal:  Int J Med Sci       Date:  2017-04-08       Impact factor: 3.738

6.  Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1.

Authors:  D Bommarito; C Hall; L S Taams; V M Corrigall
Journal:  Clin Exp Immunol       Date:  2017-04-03       Impact factor: 4.330

Review 7.  Targeting Costimulatory Pathways in Systemic Sclerosis.

Authors:  Gonçalo Boleto; Yannick Allanore; Jérôme Avouac
Journal:  Front Immunol       Date:  2018-12-18       Impact factor: 7.561

Review 8.  PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review.

Authors:  Michał Adamczyk; Dorota Krasowska
Journal:  Postepy Dermatol Alergol       Date:  2022-01-07       Impact factor: 1.837

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.